Physician profile
Michael Howard Levine
NPI 1861490484
$4,968.40
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $358 · 2021: $1,430 · 2022: $2,136 · 2023: $17.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $506.07 | 2020-2022 | |
| Abbvie INC. | $444.84 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $364.99 | 2019-2022 | |
| Eisai INC. | $305.54 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $274.21 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $269.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $230.43 | 2019-2022 | |
| Biogen, INC. | $201.54 | 2021-2022 | |
| Amgen INC. | $192.61 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $144.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.28 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $138.36 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $134.65 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $133.69 | 2022 | |
| Genzyme Corporation | $128.12 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.